Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy

Cell. 2017 Dec 14;171(7):1678-1691.e13. doi: 10.1016/j.cell.2017.11.009.


Combination cancer therapies aim to improve the probability and magnitude of therapeutic responses and reduce the likelihood of acquired resistance in an individual patient. However, drugs are tested in clinical trials on genetically diverse patient populations. We show here that patient-to-patient variability and independent drug action are sufficient to explain the superiority of many FDA-approved drug combinations in the absence of drug synergy or additivity. This is also true for combinations tested in patient-derived tumor xenografts. In a combination exhibiting independent drug action, each patient benefits solely from the drug to which his or her tumor is most sensitive, with no added benefit from other drugs. Even when drug combinations exhibit additivity or synergy in pre-clinical models, patient-to-patient variability and low cross-resistance make independent action the dominant mechanism in clinical populations. This insight represents a different way to interpret trial data and a different way to design combination therapies.

Keywords: cancer; clinical trials; combination therapy; drug synergy; mathematical modeling; patient-derived tumor xenograft; pharmacology; systems biology; tumor heterogeneity.

MeSH terms

  • Animals
  • Antineoplastic Combined Chemotherapy Protocols*
  • Biological Variation, Individual
  • Clinical Trials as Topic
  • Drug Delivery Systems
  • Drug Interactions
  • Drug Resistance, Neoplasm
  • Heterografts
  • Humans
  • Immunotherapy
  • Neoplasm Transplantation
  • Neoplasms / drug therapy*